Skip to main content

Table 1 Changes in anti-T. cruzi seroreactivity according to assay and treatment group

From: Assessing antibody decline after chemotherapy of early chronic Chagas disease patients

Antigen Number positive/examined (%) by detection assay
  Protein G: Chagas Sero K-SeT IgG1 ELISA IgG ELISA
  TSSApep-II/V/VI Lysate TSSApep-II/V/VIa Lysate TSSApep-II/V/VIa
Group A (n = 58)      
 Positive (pre-treatment) 54/58 (93.1%) 46/58 (79.3%)f 22/53b (41.5%)f 57/58 (98.3%)g 41/53b (77.4%)g
 Clear decline 25/54 (46.3%) 35/46 (76.1%) 22/22 (100%) 21/57 (36.8%) 34/41 (82.9%)e
 Seronegativisation 11/54 (20.4%) 19/46 (41.3%)h 15/22 (68.2%)i 6/57 (10.5%)h 18/41 (43.9%)i
 Remained seronegativec 4/58 (6.9%) 12/58 (20.7%) 30/53d (56.6%) 1/58 (1.7%) 12/53d (22.6%)
Group B (n = 13)      
 Positive (pre-treatment) 11/13 (84.6%) 11/13 (84.6%) 7/10b (70.0%) 13/13 (100%) 10/10b (100%)
 Clear decline 5/11 (45.5%) 6/11 (54.5%) 6/7 (85.7%) 6/13 (46.2%) 5/10 (50.0%)e
 Seronegativisation 1/11 (9.1%) 2/11 (18.2%) 5/7 (71.4%)j 1/13 (7.7%) 2/10 (20.0%)j
 Remained seronegativec 2/13 (15.4%) 2/13 (15.4%) 3/10 (30.0%) 0/13 (0%) 0/10 (0%)
  1. Group A: completed treatment; group B: reported interruption of treatment
  2. aOnly assayed for samples positive by TSSApep-II/V/VI Chagas Sero K-SeT RDT
  3. bTwo RDT-positive samples (one each from group A and group B) were not assayed by TSSApep-II/V/VI-ELISA
  4. cRemained seronegative = negative pre- and post-treatment
  5. dOne sample seroconverted (changed from negative to positive) in this assay
  6. e–jStatistically significant differences between superscript pairs are discussed in the text